Archive Newsletter

1. 07.30.26 -- Innovations To Support Scale And Efficiency In Your Process 7/30/2026

   07/30/26 Cell & Gene Newsletter

2. 07.30.26 -- Addressing The Particulate Challenge In Cell Therapy Products 7/30/2026
   07/30/26 Cell & Gene Newsletter
3. 07.29.26 -- Key Considerations for Combination Product Development 7/29/2026

   07/29/26 Cell & Gene Newsletter

4. 07.29.26 -- Full FDA Approval For TECELRA Is More Than A Regulatory Win For Solid Tumors 7/29/2026
   07/29/26 Cell & Gene Newsletter
5. 07.28.26 -- STREAM Edition: Future CGT Manufacturing Trends, AI Reality Checks, And Phase 1 Strategy 7/28/2026

   07/28/26

6. 07.28.26 -- FDA Approval Of TREGZI Signals A New Era For Precision Engineered Cell Therapy 7/28/2026
   07/28/26 Cell & Gene Newsletter
7. 07.27.26 -- Building CGT Manufacturing Capacity For The Next Commercial Era 7/27/2026
   07/27/26 Cell & Gene Newsletter
8. 07.24.26 -- Unlocking Gentler, Cost-Efficient TIL Therapy For Cold Tumors 7/24/2026
   07/24/26
9. 07.23.26 -- CGT Biotech/CDMO Transparency & Core Capabilities 7/23/2026
   07/23/26 Cell & Gene Newsletter
10. 07.22.26 -- Accelerate Your Gene Therapy Pipeline with NGS, AAV Clearance, and Virus Bank Expertise 7/22/2026

    07/22/26 Cell & Gene Newsletter